NEW STRATEGIES FOR FOLLOW UP OF BREAST CANCER PATIENTS USING CEA, TPA, CA 15-3 AND CA 50 Dedicated to Professor Janis V. Klavins
Tumor Markers in Pancreatic Cancer: A Comparative Clinical Study between CEA, CA 19-9 and CA 50 | Semantic Scholar
Tumor Markers - CA153/proGRP/CA242/PGI/PGII/Cy211 | Fapon Biotech Inc.
E. Henny Herningtyas Clinical Pathology Department, FM-UGM - ppt video online download
CEA, CA 50 and CA 242 in patients surviving colorectal cancer without recurrent disease
Receiver operating characteristic (ROC) curve analysis of the tumour markers CEA, CA 50 and CA 242 in pancreatic cancer; results from a prospective study. - Abstract - Europe PMC
Comparison of CA-50, a new tumour marker, with carcinoembryonic antigen (CEA) and alpha-fetoprotein (AFP) in patients with gastrointestinal diseases. - Abstract - Europe PMC
Serum tumor markers CEA, CA 50, TATI, and NSE in lung cancer screening
Tumour-associated trypsin inhibitor (TATI) in patients with colorectal cancer: a comparison with CEA, CA 50 and CA 242
Significance of serum tumor markers CA50 and CEA in gastric cancer
CA 242, a new tumour marker for pancreatic cancer: a comparison with CA 19-9, CA 50and CEA
Measuring Intragastric Tumor Markers in Gastric Cancer Patients: a Systematic Literature Review on Significance and Reliability
Originalien CA 19-9, CA 50 and elastase 1 as additional markers of cystic fibrosis
Tumour Markers CA 19-9 and CA 50 in Digestive Tract Malignancies